{"id":"W4380290922","doi":"10.1001/jamaneurol.2023.1625","title":"Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis","year":2023,"lang":"en","type":"article","venue":"JAMA Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; EMD Serono; Trish Multiple Sclerosis Research Foundation; Dementia Australia; Teva Pharmaceutical Industries; Royal Melbourne Hospital Neuroscience Foundation; Alexion Pharmaceuticals; Multiple Sclerosis Australia; Shionogi; Sanofi; Sanofi Genzyme; University of Melbourne; Atara Biotherapeutics; Medical Research Council; Biogen; Bristol-Myers Squibb","keywords":"Ocrelizumab; Relapsing remitting; Multiple sclerosis; Rituximab; Medicine; Dermatology; Internal medicine; Immunology; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01619828,0.0007729892,0.001948651,0.0005851625,0.0002958471,0.001242614,0.00117649,0.001913799,0.002711473],"category_scores_gemma":[0.01826121,0.0005286963,0.00641997,0.0005982881,0.0006872323,0.0007157401,0.0009568202,0.001607944,0.0003038079],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007696845,"about_ca_system_score_gemma":0.001177939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001035664,"about_ca_topic_score_gemma":0.001299673,"domain_scores_codex":[0.9819119,0.01310567,0.001487887,0.001889904,0.0009435081,0.0006610882],"domain_scores_gemma":[0.9846964,0.008179565,0.004845114,0.0009972574,0.0003639851,0.0009176614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8472016,0.001336909,0.07102728,0.002335715,0.038126,0.0002071927,0.0002279495,0.00136755,0.001142687,0.0005952618,0.001185221,0.03524657],"study_design_scores_gemma":[0.337889,0.1965572,0.3521487,0.001929858,0.08037969,0.0009164246,0.0005472485,0.01400827,0.003344863,0.004329899,0.007782243,0.0001666757],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9754652,0.02007869,0.0007646257,0.0007880982,0.000544901,0.0003027136,0.0007611146,0.00002115647,0.001273393],"genre_scores_gemma":[0.9966292,0.001811098,0.0002911742,0.0002513945,0.0002125384,0.0001130631,0.0003337116,0.000004647562,0.0003531285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01619828,"threshold_uncertainty_score":0.0856657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08027053078908819,"score_gpt":0.308107479822876,"score_spread":0.2278369490337878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}